Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Lexicon Pharmaceuticals, Inc.    LXRX

LEXICON PHARMACEUTICALS, INC. (LXRX)
Mes dernières consult.
Most popular
  Report  
 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials (USD)
Sales 2018 71,6 M
EBIT 2018 -131 M
Net income 2018 -146 M
Debt 2018 205 M
Yield 2018 -
Sales 2019 207 M
EBIT 2019 -2,90 M
Net income 2019 -3,73 M
Debt 2019 113 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 17,4x
EV / Sales2019 5,60x
Capitalization 1 045 M
More Financials
Company
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease.It also offers programs in clinical development for diabetes, irritable bowel syndrome, and carcinoid... 
More about the company
Surperformance© ratings of Lexicon Pharmaceuticals, I
Trading Rating : Investor Rating :
More Ratings
Latest news on LEXICON PHARMACEUTICALS, I
05/10LEXICON PHARMACEUTICALS : Announces Publication of New Xermelo Data in Clinical ..
AQ
05/08LEXICON PHARMACEUTICALS, INC. : Blog Exposure - Lexicon Pharma’s New XERMELO(R) ..
AC
05/04Lexicon Pharmaceuticals Announces Publication of New XERMELO® (Telotristat Et..
GL
05/04LEXICON PHARMACEUTICALS : to Present at Upcoming Investor Conference
AQ
05/03LEXICON PHARMACEUTICALS : Management's Discussion and Analysis of Financial Cond..
AQ
05/03LEXICON PHARMACEUTICALS, INC. : Results of Operations and Financial Condition (f..
AQ
05/03Lexicon Pharmaceuticals Reports First Quarter 2018 Financial Results and Prov..
GL
05/01Lexicon Pharmaceuticals to Present at Upcoming Investor Conference
GL
04/27LEXICON PHARMACEUTICALS, INC. (NASDA : LXRX) Files An 8-K Submission of Matters ..
AQ
04/26LEXICON PHARMACEUTICALS, INC. : Submission of Matters to a Vote of Security Hold..
AQ
More news
Sector news : Bio Therapeutic Drugs
05/18GLAXOSMITHKLINE : Regulators flag possible birth defect link to GSK's HIV drug
RE
05/11Trump's Plan to Cut Drug Prices Leaves Industry Relieved
DJ
05/09Drugmaker GSK rings in more change as CFO heads for exit in 2019
RE
05/08UK biotech firm Autolus joins CAR-T rush with Nasdaq IPO filing
RE
05/03Teva raises 2018 outlook, expects migraine drug approval by year-end
RE
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
2015SEEKING ALPHA'S BIOTECH WEEKLY : A Gilead Victory, Celladon Crumbles, And More 
2015Lexicon Undervalued As It Approaches A Major Event 
2015Lexicon Pharmaceuticals' (LXRX) CEO Lonnel Coats on Q1 2015 Results - Earning.. 
2015Lexicon Pharmaceuticals EPS in-line, beats on revenue 
2015Lexicon Pharmaceuticals - A Diamond In The Rough? 
Chart LEXICON PHARMACEUTICALS, I
Duration : Period :
Lexicon Pharmaceuticals, I Technical Analysis Chart | LXRX | US5288721047 | 4-Traders
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 22,7 $
Spread / Average Target 126%
EPS Revisions
Managers
NameTitle
Lonnel Coats President, Chief Executive Officer & Director
Raymond Debbane Chairman
Jeffrey L. Wade CFO, EVP-Corporate & Administrative Affairs
Pablo Lapuerta Chief Medical Officer & Executive Vice President
Frank P. Palantoni Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
LEXICON PHARMACEUTICALS, INC.12.10%1 045
GILEAD SCIENCES-5.05%88 140
VERTEX PHARMACEUTICALS4.08%39 840
REGENERON PHARMACEUTICALS-19.72%32 633
GENMAB23.23%12 171
BEIGENE LTD (ADR)99.09%10 130